(lp0
S"ArQule, Inc.  Shares Dive as HCC Trial Fails to Meet Primary Endpoint Smarter Analyst - Feb 17, 2017 ArQule, Inc.  shares tumbled nearly 20% this morning after investors learned that the company's METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma  did not meet its primary endpoint of improving overall survival.ArQule's lead product candidate tivantinib flunks late-stage liver cancer ... - Seeking Alpha"
p1
aS"ArQule Inc. ARQL  Wall Street Journal - Feb 1, 2002 News ArQule Inc.ARQL. No news for ARQL in the past two years. Key Stock Data ? P/E Ratio : The Price to Earnings  ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted ..."
p2
aS'ArQule Is Undervalued Going Into Catalyst Events Seeking Alpha - Oct 21, 2016 ArQule  is a small biopharmaceutical company  engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.'
p3
aS'Annual Global Healthcare Conference on February 15, 2017 Business Wire  - Feb 8, 2017 BURLINGTON, Mass.----ArQule, Inc.  today announced that Paolo Pucci, Chief Executive Officer, and Dr.'
p4
aS'ArQule Reports Fourth Quarter and Full Year 2016 Financial Results Yahoo Finance - Mar 7, 2017 ArQule, Inc.  today announced its financial results for the fourth quarter and full year of 2016. For the quarter ended December 31, 2016, the Company reported a net loss of $6,820,000 or $0.10 per share, compared with net loss of $2,852,000 or ...'
p5
aS'Latest Tivantinib Failure Hits ArQule Despite Its Irrelevance Seeking Alpha - Jan 15, 2013 ArQule  just cannot seem to get any satisfaction from its c-Met kinase inhibitor tivantinib. Even worse for the Massachusetts biotech, its shares have taken a hit despite the latest failure coming in a study with little practical relevance ...'
p6
aS"Safra Catz, Oracle 's insider Sold 3000000 Shares; ArQule, Inc. (ARQL ... MoneyMakingArticles - 12 hours ago After the disclosing of a public document filled with SEC; an important and substantial sale became apparent. The Chief Executive Officer of Oracle Corp, Safra Catz; finalized a significant sale in the open market by selling 3,000,000 shares at the ..."
p7
aS"Sell-Side Analyst's Predictions: ArQule, Inc. , Array BioPharma Inc.  The USA Commerce - Feb 21, 2017 Shares of ArQule, Inc.  dropped -18.37% to $1.20. During the trading on 02/17/2017, Company's stock ranged from $1.13 to $1.26."
p8
aS'ArQule, Inc.  Upgraded by Zacks Investment Research to Hold Chaffey Breeze - Mar 9, 2017 ArQule, Inc. logo Zacks Investment Research upgraded shares of ArQule, Inc.  from a sell rating to a hold rating in a research note published on Wednesday morning.ArQule, Inc.  Upgraded to Hold at Zacks Investment Research - BBNSAverage Price Target Of 3.08 Issued For ArQule, Inc.  - Fiscal Standard'
p9
aS'Breaking Down: ArQule Inc  Stock Drop Below Support -- Technicals ... CML News - Mar 20, 2017 Breaking Down: ArQule Inc  has hit extreme technical weakness -- watch the stochastics and technical oscillators for any kind of momentum signals if you are looking for a turnaround.'
p10
a.